Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Proteus Syndrome 1

Interventions

pembrolizumab 382Carboplatin 280Specimen Handling 266Nivolumab 256Magnetic Resonance Spectroscopy 247Cyclophosphamide 243Cisplatin 215Paclitaxel 209Radiotherapy 194Biopsy 171Gemcitabine 156Dexamethasone 149durvalumab 148atezolizumab 127Rituximab 122Doxorubicin 119Bevacizumab 115Ipilimumab 114Lenalidomide 112Radiation 111Pemetrexed 104Docetaxel 104Etoposide 103venetoclax 98fludarabine 97Capecitabine 94Radiosurgery 93Fluorouracil 93Prednisone 90Oxaliplatin 90

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Miransertib × 1 year × Clear all
NCT04316546 2026-06-03

MK-7075 (Miransertib) in Proteus Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
38 enrolled

Proteus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡